Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | AZD1208 + Vemurafenib |
| Indication/Tumor Type | papillary thyroid carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | papillary thyroid carcinoma | sensitive | AZD1208 + Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Zelboraf (vemurafenib) and AZD1208 synergistically inhibited viability and colony formation of papillary thyroid carcinoma cell lines harboring BRAF V600E in culture (PMID: 38593698). | 38593698 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38593698) | Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms. | Full reference... |